Pacira BioSciences, Inc. (PCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 3:04 AM ET
Pacira BioSciences, Inc. (PCRX) Stock Forecast
Analysts expect Pacira BioSciences (PCRX) to earn $2.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $754.33M. Of 9 analysts, 0 rate the stock Buy or Strong Buy, 9 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. All 9 rate it Hold.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 9 | 100.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 19.3% and revenue estimates rise 4.7%.
- Fiscal year ending Dec 31, 2026
- $2.90
- EPS consensus, revenue $754.33M
- Fiscal year ending Dec 31, 2027
- $3.46
- EPS consensus, revenue $790.02M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.90 | $2.72 to $2.99 | 9 | $754.33M | $747.83M to $759.40M | 8 |
| Dec 31, 2027 | $3.46 | $3.05 to $3.94 | 9 | $790.02M | $761.82M to $812.70M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.84 for the quarter ending Dec 31, 2026 to $0.73 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.84 | $0.70 to $0.98 | 11 | $204.69M | $189.05M to $214.40M | 10 |
| Mar 31, 2027 | $0.73 | $0.65 to $0.89 | 4 | $181.51M | $175.69M to $185.10M | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.7% from $2.88.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.90 | $2.89 | $2.89 | $2.95 | $2.88 | +0.7% |
| Fiscal year ending Dec 31, 2027 | $3.46 | $3.44 | $3.44 | $3.49 | $3.65 | -5.2% |
| Quarter ending Mar 31, 2027 | $0.73 | $0.76 | $0.77 | $0.80 | $0.81 | -9.0% |
Frequently Asked Questions About PCRX
What is the PCRX stock forecast?
Consensus analyst estimates put Pacira BioSciences's EPS at $2.90 for the fiscal year ending Dec 31, 2026, on revenue of $754.33M. The consensus rating from 9 analysts is Hold.
How do analysts rate PCRX stock?
Of 9 analysts covering Pacira BioSciences, 0 rate it Strong Buy, 0 Buy, 9 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PCRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.90, with estimates from $2.72 to $2.99 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.46, with estimates from $3.05 to $3.94 from 9 analysts.
What revenue do analysts expect from Pacira BioSciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $754.33M, with estimates from $747.83M to $759.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $790.02M, with estimates from $761.82M to $812.70M.
How many analysts cover PCRX?
9 analysts rate Pacira BioSciences stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors